Is PLUR or PMCB more undervalued in 2026?

CirclFi compares Pluri Inc. (PLUR) and PharmaCyte Biotech, Inc. (PMCB) using 13 institutional-grade valuation models. PLUR has a Quality of Company score of 5.6/10 while PMCB scores 5.1/10.

Which is a better buy — PLUR or PMCB?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do PLUR and PMCB valuations compare?

PLUR at $2.32 and PMCB at $0.83 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

PLUR vs PMCB Valuation Comparison 2026 — Intrinsic Value Analysis

PLUR

Biological Products, (No Diagnostic Substances)

Pluri Inc.

Quality

5.6

out of 10

Value Trap

LOW

Price

$2.32

Last close

Models

10/13

Active

PMCB

Biological Products, (No Diagnostic Substances)

PharmaCyte Biotech, Inc.

Quality

5.1

out of 10

Value Trap

SAFE

Price

$0.83

Last close

Models

3/13

Active

Model-by-Model Comparison

Model	Type	PLUR Fair Value	PLUR Upside	PMCB Fair Value	PMCB Upside
Bayesian DCF	Intrinsic	$0.28	-87.9%	—	—
Earnings Power Value	Intrinsic	$0.82	-75.6%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$3.95	+70.4%	$2.46	+194.8%
PWERM	Option-Based	$4.38	+88.8%	$2.23	+167.6%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for PLUR vs PMCB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PLUR vs PMCB — Which Stock Is More Undervalued?

PLUR scores higher with a 5.6/10 quality rating vs PMCB's 5.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Pluri Inc. (PLUR) and PharmaCyte Biotech, Inc. (PMCB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PLUR currently trades at $2.32 with a QOC of 5.6/10, while PMCB trades at $0.83 with a QOC of 5.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).